source
- FDA advisory panel votes to expand use of four untested peptides despite safety concernsAn FDA advisory committee narrowly voted to recommend adding four peptides to the agency's 503A Bulks List, a registry that would allow compounding pharmacies to use them in custom medications. The…
- Sanofi stops development of eczema drug amlitelimab after mixed trial resultsSanofi announced on Friday that it is halting further development of amlitelimab for atopic dermatitis, a drug it had once promoted as a potential successor to its blockbuster Dupixent. The compan…